ctDNA analysis
ctDNA analysis is an intervention with 9 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
3 of 3 finished
0.0%
0 ended early
4
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib
The circTeloDIAG: Liquid Biopsy for Glioma Tumor
CAcTUS - Circulating Tumour DNA Guided Switch
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
Clinical Trials (9)
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib
The circTeloDIAG: Liquid Biopsy for Glioma Tumor
CAcTUS - Circulating Tumour DNA Guided Switch
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
EGFR Mutations on ctDNA in Patients With Advanced NSCLC
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
All 9 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 9